In advanced NSCLC, responses to ALK-TKI are typically seen within ~2 months.27) The NAUTIKA1 and ALNEO trials showed that 8 weeks of neoadjuvant alectinib achieved both efficacy and tolerability,26,28) although severe adverse events such as Grade 3 interstitial pneumonitis have been reported. The gene discussed is ALK; the disease is non-small cell lung carcinoma.